We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Colorectal Cancer Screening Test Is Simple and Convenient

By LabMedica International staff writers
Posted on 06 Oct 2008
A noninvasive, safe, simple, and convenient screening test for colorectal cancer uses only a single stool sample.

Called ColoSure, the assay assesses the presence of active colorectal cancer in average-risk individuals. More...
The assay is performed, after a simple collection process, on a complete bowel movement, and it examines DNA in exfoliated colon cells for a change that can indicate the presence of cancer. The ColoSure assay can be used as a part of a comprehensive, ongoing colorectal cancer-screening program, and is complementary to both traditional and virtual colonoscopies. ColoSure has a sensitivity range of 72-77%, and a specificity range of 83-94%

The clinical test looks for a DNA change in the vimentin gene, which is important to immunity and other important cell processes in the body. If the vimentin gene is hyper-methylated, or "turned off,” this could indicate colon cancer. A study, published in the September 2008 issue of the American Journal of Gastroenterology, showed that detecting methylated vimentin DNA in feces was both highly sensitive and highly specific for detecting early-stage, curable colon cancers.

DNA Direct (San Francisco, CA, USA) announced that the ColoSure screening test is now available and can be ordered through the company's website. DNA Direct's personalized, web-enabled report for recipients of the ColoSure test includes an overview of test results, a lab report, a letter to bring to their physician, and recommended follow-up.

Reports also reinforce awareness of the signs and symptoms of colorectal cancer, and include an option to schedule a reminder for the patient's next screening. Finally, the report includes a section on how ColoSure works, ways to change contributing lifestyle factors, a list of resources for patients and important facts about colorectal cancer.

At least 60% of Americans age 50 and older have never been screened for colorectal cancer, even though the American Cancer Society recommends a lifelong screening program for those aged 50 or older, including a colonoscopy every 10 years. Each year, nearly 150,000 new cases are diagnosed, and up to 50,000 people die of colorectal cancer. If caught early, the survival rate is close to 95%--but 50% of patients with colorectal cancer are diagnosed with advanced disease, which is less likely to be surgically curable.

Related Links:

DNA Direct


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.